About: Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19
Creator	Butin-Israeli, Veronika Chatterjee, Swapan Munoz, M Nilda, Maria Piccaluga, Pier Saha, Snigdha
source	Medline; PMC
abstract	The coronavirus disease 2019 (COVID-19), is a highly contagious transmittable disease caused by a recently discovered coronavirus, pathogenic SARS-CoV-2. Followed by the emergence of highly pathogenic coronaviruses in 2003 SARS-CoV, in 2012 MERS-CoV, now in 2019 pathogenic SARS-CoV-2, is associated with a global “pandemic” situation. In humans, the effects of these viruses are correlated with viral pneumonia, severe respiratory tract infections. It is believed that interaction between angiotensin converting enzyme 2 (ACE2) cell receptor and viral Spike protein mediates the coronavirus entry into human respiratory epithelial cells and establishes the host tropism. ACE2 receptor is highly expressed in airway epithelial cells. Along with viral-receptor interaction, proteolytic cleavability of S protein has been considered as the determinant of disease severity. Several studies highlight the occurrence of impaired host immune response and expression of excessive inflammatory response especially cytokines against viral infection. The mechanisms of SARS-CoV-2 induced acute lung injury are still undefined; however, the term cytokine storm has now been recognized to be closely associated with COVID-19. The levels of inflammatory mediators from cytokine storm cause damage to the host cells. In particular, the proinflammatory cytokine IL-6 appears to be the key mediator in early phase of virus-receptor interaction; however, secreted IL-6 might not be representative of lung inflammation. Understanding the cellular, and molecular factors involved in immune dysregulation and the high virulence capacity of COVID-19 will help in potential targeted therapy against it. “Drug repurposing” and “molecular docking analysis” is considered as an attractive alternative approach in analyzing suitable drug candidates to combat SARS-CoV-2 infection. Globally, extensive research is in progress to discover a new vaccine for novel COVID-19. Moreover, our review mainly focuses on the most state-of-the-art therapeutic approach mediated by “Mannose-binding lectin (MBL).” One of the most significant molecules of innate immunity is MBL. It plays a major role in the activation of the complement system as an ante-antibody prior to the response of any particular antibody. Recombinant human MBL can be used as immunomodulators against SARS-CoV-2.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.3389/fmolb.2020.00196
bibo:pmid	32850977
has license	cc-by
sha1sum (hex)	0b11c09aa76c43011dd4c36f4c4f59572b7c893a
schema:url	https://doi.org/10.3389/fmolb.2020.00196
resource representing a document's title	Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19
has PubMed Central identifier	PMC7431665
has PubMed identifier	32850977
schema:publication	Front Mol Biosci
resource representing a document's body	covid:0b11c09aa76c43011dd4c36f4c4f59572b7c893a#body_text
is schema:about of	named entity 'vaccine' named entity 'host' named entity 'Spike' named entity 'IL-6' named entity 'proteolytic' named entity 'highly' named entity 'SARS-CoV-2' named entity 'mechanisms' named entity 'Pathogenesis' named entity 'Molecular' named entity 'Strategy' named entity 'OUR' named entity 'CORONAVIRUSES' named entity 'CORONAVIRUS' named entity 'ANTIBODY' named entity 'HOST IMMUNE RESPONSE' named entity 'LUNG INFLAMMATION' named entity 'EFFECTS' named entity 'DOCKING' named entity 'CAPACITY' named entity 'OCCURRENCE' named entity 'ART' named entity 'ACE2' named entity 'COMBAT' named entity 'ROLE' named entity 'CONSIDERED' named entity 'USED' named entity 'ONE OF' named entity 'MEDIATOR' named entity 'PHASE' named entity 'APPROACH' named entity 'SUITABLE' named entity 'DAMAGE' named entity 'LEVELS' named entity 'RESEARCH' named entity '2019' named entity 'INTERACTION' named entity 'DISEASE' named entity 'IN PROGRESS' named entity 'VIRUS' named entity 'HIGH' named entity 'POTENTIAL' named entity 'CAUSE' named entity 'MECHANISMS' named entity 'NOVEL' named entity 'mediated' named entity 'interaction' named entity 'interaction' named entity 'protein' named entity 'correlated' named entity 'early' named entity 'coronavirus' named entity 'highly' named entity 'recognized' named entity 'Understanding' named entity 'high' named entity 'induced' named entity 'cells' named entity 'viral' named entity 'humans' named entity 'term' named entity '2012' named entity 'lectin' named entity 'targeted therapy' named entity 'Recombinant' named entity 'immunomodulators' named entity 'epithelial cells' named entity 'receptor' named entity 'acute lung injury' named entity 'cytokines' named entity 'complement' named entity 'coronavirus' named entity 'antibody' named entity 'COVID' named entity 'viral infection' named entity 'molecular docking'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software